These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

393 related articles for article (PubMed ID: 37249833)

  • 1. Current Approaches to Neoadjuvant Immunotherapy in Resectable Non-small Cell Lung Cancer.
    Parekh J; Parikh K; Reuss JE; Friedlaender A; Addeo A
    Curr Oncol Rep; 2023 Aug; 25(8):913-922. PubMed ID: 37249833
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perioperative Systemic Therapy for Resectable Non-Small Cell Lung Cancer.
    Muthusamy B; Patil PD; Pennell NA
    J Natl Compr Canc Netw; 2022 Aug; 20(8):953-961. PubMed ID: 35948038
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The emerging perioperative treatment paradigm for non-small cell lung cancer: a narrative review.
    Christopoulos P
    Chin Clin Oncol; 2024 Feb; 13(1):12. PubMed ID: 38372058
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Current status and future perspectives on immunotherapy in neoadjuvant therapy of resectable non-small cell lung cancer.
    Liu X; Xing H; Liu H; Chen J
    Asia Pac J Clin Oncol; 2022 Aug; 18(4):335-343. PubMed ID: 34811893
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Striving toward Improved Outcomes for Surgically Resectable Non-Small Cell Lung Cancer: the Promise and Challenges of Neoadjuvant Immunotherapy.
    Gentzler RD; Riley DO; Martin LW
    Curr Oncol Rep; 2020 Aug; 22(11):109. PubMed ID: 32803520
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant Immunotherapy for Non-Small Cell Lung Cancer.
    Sanber K; Rosner S; Forde PM; Marrone KA
    BioDrugs; 2023 Nov; 37(6):775-791. PubMed ID: 37603233
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Progress in Neoadjuvant Immunotherapies for Resectable Non-small Cell Lung Cancer].
    Wang S; Mao Y
    Zhongguo Fei Ai Za Zhi; 2020 May; 23(5):371-380. PubMed ID: 32283581
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Neoadjuvant Chemoimmunotherapy in Patients with Resectable Non-small Cell Lung Cancer.
    Gutierrez-Sainz L; Cruz-Castellanos P; Higuera O; de Castro-Carpeño J
    Curr Treat Options Oncol; 2021 Aug; 22(10):91. PubMed ID: 34424417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neoadjuvant Immunotherapy for NSCLC: Current Concepts and Future Approaches.
    Uprety D; Mandrekar SJ; Wigle D; Roden AC; Adjei AA
    J Thorac Oncol; 2020 Aug; 15(8):1281-1297. PubMed ID: 32522713
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neoadjuvant immunotherapy in resectable non-small cell lung cancer.
    Lochrin SE; Forde PM
    Clin Adv Hematol Oncol; 2023 Aug; (8):415-423. PubMed ID: 37530615
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Induction or neoadjuvant therapy in resectable non-small cell lung cancer.
    Langer CJ
    Semin Oncol; 1999 Oct; 26(5 Suppl 15):34-9. PubMed ID: 10566609
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Neoadjuvant treatment of early-stage resectable non-small-cell lung cancer.
    Betticher DC; Rosell R
    Lung Cancer; 2004 Dec; 46 Suppl 2():S23-32. PubMed ID: 15698528
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neoadjuvant immunotherapy in nonsmall cell lung cancer.
    Pall G
    Curr Opin Oncol; 2021 Jan; 33(1):59-63. PubMed ID: 33229874
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacodynamics of Pre-Operative PD1 checkpoint blockade and receptor activator of NFkB ligand (RANKL) inhibition in non-small cell lung cancer (NSCLC): study protocol for a multicentre, open-label, phase 1B/2, translational trial (POPCORN).
    Ahern E; Cubitt A; Ballard E; Teng MWL; Dougall WC; Smyth MJ; Godbolt D; Naidoo R; Goldrick A; Hughes BGM
    Trials; 2019 Dec; 20(1):753. PubMed ID: 31856909
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in clinical trials on perioperative immune checkpoint inhibitors for resectable non-small cell lung cancer: A comprehensive review.
    Cui S; Wang N; Liang Y; Meng Y; Shu X; Kong F
    Int Immunopharmacol; 2024 Nov; 141():112903. PubMed ID: 39146783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer].
    Qi C; Tian P; Li W
    Zhongguo Fei Ai Za Zhi; 2024 Feb; 27(2):138-146. PubMed ID: 38453446
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Neoadjuvant immunotherapy for non-small cell lung cancer: State of the art.
    Kang J; Zhang C; Zhong WZ
    Cancer Commun (Lond); 2021 Apr; 41(4):287-302. PubMed ID: 33689225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Interim analysis of the efficiency and safety of neoadjuvant PD-1 inhibitor (sintilimab) combined with chemotherapy (nab-paclitaxel and carboplatin) in potentially resectable stage IIIA/IIIB non-small cell lung cancer: a single-arm, phase 2 trial.
    Sun C; Liu Y; Zhang P; Wang X; Xu Y; Lin X; Ma X; Guo Y; Qiu S; Shao G; Yang Z; Ma K
    J Cancer Res Clin Oncol; 2023 Feb; 149(2):819-831. PubMed ID: 35192053
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neoadjuvant anti-programmed Death-1 immunotherapy by Pembrolizumab in resectable nodal positive stage II/IIIa non-small-cell lung cancer (NSCLC): the NEOMUN trial.
    Eichhorn F; Klotz LV; Bischoff H; Thomas M; Lasitschka F; Winter H; Hoffmann H; Eichhorn ME
    BMC Cancer; 2019 May; 19(1):413. PubMed ID: 31046714
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapy in patients with early stage resectable nonsmall cell lung cancer.
    Ghysen K; Vansteenkiste J
    Curr Opin Oncol; 2019 Jan; 31(1):13-17. PubMed ID: 30325753
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 20.